Fresenius Kabi

Recent News About Fresenius Kabi View More

• 

  Shareholder suit alleges Akorn, Fresenius merger benefits leadership, doesn't do enough for investors

  By Scott Holland | Friday, May 5, 2017 @ 4:48pm

  A group of investors wants a court to keep German pharmaceutical firm Fresenius from buying Illinois drug maker Akorn, saying shareholders won’t get enough from the deal, which is valued at more than $4 billion.

  ---